Skip to content

Author

Mohammed H. al Mughram

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Structure‐Guided Identification of Flavonoid Inhibitors Targeting PE_PGRS17 in Mycobacterium tuberculosis : Insights From an Integrated In Silico Strategy

PE_PGRS17, a surface‐associated antigen of Mycobacterium tuberculosis (Mtb), contributes to immune evasion and intracellular survival within macrophages and therefore represents a potentially relevant but underexplored therapeutic target. Here, a curated library of flavonoid compounds was screened against PE_PGRS...

J. Firdaus, Amjad I. Oraibi, Mohammed H. al Mughram et al. · 0 citations
Oct 2026

Finding Novel Inhibitors of FMS-like Tyrosine Kinase 3 from Selected FDA-approved Anticancer Drugs: Insights from Molecular Docking, MD Simulations, and ADMET Profiling.

BACKGROUND Wild-type FLT3 (WT-FLT3) has emerged as a relevant molecular target in Acute Myeloid Leukemia (AML), with increasing evidence implicating its role in leukemic proliferation and resistance, even in the absence of FLT3 mutations. Although gilteritinib is an approved FLT3 inhibitor, its efficacy in WT-FLT3 AML...

Mohammed H. al Mughram, L. J. Babatola, Md. Nazim Uddin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.